Skip to main content
Premium Trial:

Request an Annual Quote

Piet Borst, Jose Baselga, Matt van de Rijn, David Kerr, C. Kent Osborne, Joe Gray

Premium

Agendia appointed last week six new members to its clinical and scientific advisory board. The advisors will review early research programs and provide academic and clinical evaluations. The advisory board will be chaired by Piet Borst, emeritus director of the Netherlands Cancer Institute. Members include Jose Baselga, professor of medicine at Vall d'Hebron University Hospital in Barcelona, Spain; Matt van de Rijn, professor of pathology a Stanford University; David Kerr, professor of clinical pharmacology at the University of Oxford in the UK; C. Kent Osborne, professor of medicine at Baylor College of Medicine; and Joe Gray, director of the life sciences division at the Lawrence Berkeley National Laboratory.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.